The 2009 Supplement to The Journal of Nuclear Medicine: Personalizing Cancer Therapy with FDG PET: From RECIST to PERCIST

Understand the clinical role of FDG PET in monitoring therapy responses in cancer patients. Each contribution presents the current evidence for FDG PET as a tool for cancer treatment monitoring, describes and tabulates available information and critically assesses the impact of FDG PET on the management of cancer patients and for individualizing therapeutic strategies. This guide will help you and your patients in choosing the best course of action with FDG PET in cancer treatment. Become knowledgeable in the following facets of medicine: *Approaches for Assessing Tumor Response to Therapy *Standards for PET image acquisition and quantitative data analysis *Therapy response in lymphoma *Role of FDG PET in Response Assessment in Non-Small Cell Lung Cancer *Monitoring and Predicting Therapy Response with FDG-PET in Colorectal Cancer: A Systematic Review *Therapy Response in Breast Cancer *Role of FDG PET in Assessing Therapy Response in Cancer of the Cervix and Ovaries *Monitoring Therapy Response in Head and Neck Squamous Cell Carcinoma With PET Imaging *FDG-PET and -PET/CT for therapy response assessment in esophageal cancer *Monitoring Predominantly Cytostatic Treatment Response with FDG PET *Radiopharmaceuticals in Pre-Clinical and Clinical Development for Therapy Monitoring with PET *From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors